Skip to content

Rudy Schreiber

4 papers in the library · 76 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

Circulating MicroRNAs and Their Associations with Neurotrophic, Inflammatory and Glutamate Markers in Healthy Volunteers

bioRxiv (Cold Spring Harbor Laboratory) August 10, 2026 Aedan O'Shea, Natasha L. Mason, Jacco Briede et al. preprint

Abstract Psilocybin acutely alters neurotrophic, neurochemical, and immune markers, but the relationships between these responses and circulating microRNAs (miRNAs), i.e. non-coding RNAs that regulate post-transcriptional gene expression, remain unclear. In a randomized, double-blind, placebo-controlled study of 62 healthy adults who received psilocybin (0.17 mg/kg) or placebo, we previously...

Examining the Psychoactive Differences between Kratom Strains

International Journal of Environmental Research and Public Health July 21, 2023 Guido Huisman, Maximilian Menke, Oliver Grundmann et al. 13 citations

) is a Southeast Asian plant containing various alkaloids that induce pharmacological effects in humans. In Western countries, online vendors sell a variety of different kratom strains which are marketed to have distinct effect profiles. However, as of yet such marketing claims are unsubstantiated, and therefore the current study investigated whether differently colored kratom products can...

DOI: 10.3390/ijerph20146425 (opens in new tab) Traditional medicine Population Advertising Environmental health +1

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Psychopharmacology March 29, 2022 Manon M.j. van den Berg, Igor Magaraggia, Rudy Schreiber et al. 14 citations

Rationale: Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration. The lack of an appropriate placebo control group-as patients are often able to discriminate the subjective effects of the drug-and an incomplete understanding of...

DOI: 10.1007/s00213-022-06106-8 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Antidepressants Brain research

Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach

Neurobiology of Learning and Memory May 25, 2021 Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber 49 citations

The high symptomatic and biological heterogeneity of major depressive disorder (MDD) makes it very difficult to find broadly efficacious treatments that work against all symptoms. Concentrating on single core symptoms that are biologically well understood might consist of a more viable approach. The Research Domain Criteria (RDoC) framework is a trans-diagnostic dimensional approach that...